Asker Healthcare Group stock
ASKER.STSTOAsker Healthcare Group AB, HealthcareISIN SE0024171458
61Score 61 out of 100, Neutral
Price and trend
68 / 100
Price history
−21% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 0.2% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 50).
The price is 23% below its 52-week high. Largest decline in 2 years: 57% (July 2025 to September 2026).
Chart figures for advanced users
- SMA 50$6.83
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.34
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)50
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.70
- The lowest closing price of the last twelve months.
- Resistance$9.50
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Asker Healthcare Group AB belongs to the Medical (Distribution) industry (Sweden) and, with a market value of $2.81B, is number 9 of 17 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.69B (up 11.7% year on year) and earnings of $49.54M (up 36.7%).
- For fiscal 2026, analysts expect on average revenue of $1.95B (up 15.1%) and adjusted earnings per share of $0.28 (up 19.4%).
Show more
- MEQIRI Score 61 out of 100 (Neutral): rank 256 of 714 in Healthcare, median 53.
- The P/E is 37.4 (Medical (Distribution) median 26.9, own median of recent years 67.5).
- Our model puts fair value at $6.23, with the price 20% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 15.7% a year since 2021, Medical (Distribution) median 9.5%.Growth 84
Weaknesses
- Interest barely coveredOperating profit covers interest only 2.2 times.Stability 46
Its standout strengths are growth and fundamentals, while stability and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 60 to 61.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $4.45 and expensive above $10.39 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $7.20 (cash-flow model) and $5.27 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $5.65, at 6.3% it would be $7.09.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (26.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 13.5% on the twelve months before. Revenue has grown strongly since 2021, at around 16% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 36%, operating 8%, net 3%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 10 Feb 2027in 90 days
- Last reported
- 4 Nov 2026EPS reported $0.06 (expected $0.06)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.28−0.5%
- Revenue
- $1.95B+0.1%
- Earnings per share
- $0.33+0.6%
- Revenue
- $2.13B+0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Asker Healthcare Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Distribution)
The next larger and next smaller companies by market value
- Shanghai Pharmaceuticals Holding601607.SS $9.01B53
- Sinopharm Group1099.HK $6.67B58
- GalenicaGALE.SW $5.42B60
- AmplifonAMP.MI $3.68B49
- Sopharma ADSPH.WA $1.9B57
- Redcare PharmacyRDC.DE $1.6B47
- UnipharUPR.IR $1.27B57
- Akso Health GroupAHG $1.15B36
ETFs that hold Asker Healthcare Group
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares OMX Stockholm Capped UCITS ETFOM3X | 0.19% | 0.10% | €197.05M |
| WisdomTree Europe SmallCap Dividend UCITS ETFWTES | 0.19% | 0.38% | €86.74M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.09% | 0.30% | €3.43B |
Show 5 more
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.04% | 0.30% | €810.11M |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.04% | 0.23% | €319.31M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.35% | €434.1M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = SEK 9.9317)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 27 Mar 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.